Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update

Matrix metalloproteinases (MMPs) are known to be upregulated in inflammatory bowel disease (IBD) and other inflammatory conditions, but while their involvement is clear, their role in many settings has yet to be determined. Studies of the involvement of MMPs in IBD since 2006 have revealed an array of immune and stromal cells which release the proteases in response to inflammatory cytokines and growth factors. Through digestion of the extracellular matrix and cleavage of bioactive proteins, a huge diversity of roles have been revealed for the MMPs in IBD, where they have been shown to regulate epithelial barrier function, immune response, angiogenesis, fibrosis, and wound healing. For this reason, MMPs have been recognised as potential biomarkers for disease activity in IBD and inhibition remains a huge area of interest. This review describes new roles of MMPs in the pathophysiology of IBD and suggests future directions for the development of treatment strategies in this condition.

[1]  D. Shaw,et al.  Angiogenesis blockade as a new therapeutic approach to experimental colitis , 2006, Gut.

[2]  F. Paolicchi,et al.  Mycobacterium avium subsp. paratuberculosis: presencia en los alimentos y su relación con la enfermedad de Crohn , 2007 .

[3]  J. Fletcher,et al.  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.

[4]  M. Cola,et al.  Inhibitor of PI3Kγ ameliorates TNBS‐induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells , 2011, British journal of pharmacology.

[5]  Judy H. Cho,et al.  A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.

[6]  E. Roeb,et al.  Presence of intestinal Mycobacterium avium subspecies paratuberculosis (MAP) DNA is not associated with altered MMP expression in ulcerative colitis , 2011, BMC gastroenterology.

[7]  M. Lukáš Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer , 2010, Digestive Diseases.

[8]  M. Federici,et al.  Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. , 2012, Gastroenterology.

[9]  A. Kraneveld,et al.  Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease , 2013, Gut.

[10]  D. Podolsky The current future understanding of inflammatory bowel disease. , 2002, Best practice & research. Clinical gastroenterology.

[11]  S. Wenzel,et al.  Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. , 2007, The Journal of allergy and clinical immunology.

[12]  Marloes A. A. Schepens,et al.  Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. , 2009, The Journal of nutrition.

[13]  A. Sabatino,et al.  Role of Macrophage Metalloelastase in Gut Inflammation , 2006, Annals of the New York Academy of Sciences.

[14]  K. Hahm,et al.  Prevention of Colitis-Associated Carcinogenesis with Infliximab , 2010, Cancer Prevention Research.

[15]  P. Garg,et al.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[16]  E. Mazzon,et al.  Matrix metalloproteinase‐9 and metalloproteinase‐2 activity and expression is reduced by melatonin during experimental colitis , 2008, Journal of pineal research.

[17]  K. Rhee,et al.  Matrilysin‐1 (MMP7) cleaves galectin‐3 and inhibits wound healing in intestinal epithelial cells , 2011, Inflammatory bowel diseases.

[18]  J. Fletcher,et al.  Erratum: EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging (American Journal of Gastroenterology (2013) 108 (1891-1900) DOI: 10 , 2014 .

[19]  A. Catto-Smith,et al.  Expression profile of genes involved in pathogenesis of pediatric Crohn's disease , 2012, Journal of gastroenterology and hepatology.

[20]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[21]  G. Bancroft,et al.  Production of Matrix Metalloproteinases in Response to Mycobacterial Infection , 2001, Infection and Immunity.

[22]  M. Comalada,et al.  The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. , 2011, Biochemical pharmacology.

[23]  M. Washington,et al.  Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling , 2013, Gut.

[24]  Jialiang Hu,et al.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.

[25]  J. Satsangi,et al.  A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. , 2001, Gastroenterology.

[26]  T. Kirkegaard,et al.  Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium , 2009, Clinical and experimental immunology.

[27]  S. Chi,et al.  Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. , 2011, Molecular nutrition & food research.

[28]  T. Macdonald,et al.  Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 , 2006, Gut.

[29]  Peasad Devarajan Neutrophil gelatinase‐associated lipocalin (NGAL): A new marker of kidney disease , 2008, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[30]  A. Morgan,et al.  Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. , 2011, Human immunology.

[31]  K. Shirouzu,et al.  Increased claudin-1 protein expression contributes to tumorigenesis in ulcerative colitis-associated colorectal cancer. , 2010, Anticancer research.

[32]  H. Steinhart,et al.  IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 ‐ Inflammatory bowel disease task force meeting , 2011, Inflammatory bowel diseases.

[33]  Carlos López-Otín,et al.  Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.

[34]  J. Terwilliger,et al.  Two stage genome–wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12 , 1996, Nature Genetics.

[35]  Judy H. Cho,et al.  The Nod2 Gene in Crohn's Disease: Implications for Future Research Into the Genetics and Immunology of Crohn's Disease , 2001, Inflammatory bowel diseases.

[36]  C. López-Otín,et al.  Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF , 2013, EMBO molecular medicine.

[37]  S. Sanyal,et al.  The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[38]  Jing-Wei Mao,et al.  Expression of matrix metalloproteinase-1 and tumor necrosis factor-α in ulcerative colitis , 2007 .

[39]  Steven C Ricke,et al.  Current perspectives on Mycobacterium avium subsp. paratuberculosis, Johne’s disease, and Crohn’s disease: a Review , 2011, Critical reviews in microbiology.

[40]  P. E. Van den Steen,et al.  Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.

[41]  G. Jena,et al.  Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[42]  T. Ayabe,et al.  Bactericidal Activity of Mouse α-Defensin Cryptdin-4 Predominantly Affects Noncommensal Bacteria , 2010, Journal of Innate Immunity.

[43]  Didier Merlin,et al.  Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. , 2010, Cancer research.

[44]  C. Overall,et al.  Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. , 2010, Biochimica et biophysica acta.

[45]  E. Quintero,et al.  Increased Activity and Expression of Gelatinases in Ischemic Colitis , 2006, Digestive Diseases and Sciences.

[46]  X. Tan,et al.  Correlation of Plasma MMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis , 2009, Mediators of inflammation.

[47]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[48]  G. Kolios,et al.  Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. , 2013, Journal of Crohn's & colitis.

[49]  S. Rose-John,et al.  TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis , 2013, EMBO molecular medicine.

[50]  Federico Díaz-González,et al.  Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. , 2006, European journal of cancer.

[51]  B. Zilberstein,et al.  Bacterial translocation: Overview of mechanisms and clinical impact , 2007, Journal of gastroenterology and hepatology.

[52]  D. Zurakowski,et al.  Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[53]  S. García-Mauriño,et al.  Melatonin, autophagy and intestinal bowel disease. , 2014, Current pharmaceutical design.

[54]  A. Sabatino,et al.  CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[55]  K. Kolho,et al.  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values , 2009, International Journal of Colorectal Disease.

[56]  A. Franke,et al.  Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[57]  A. Steinmeyer,et al.  The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[58]  M. Milla,et al.  Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. , 2010, Clinical immunology.

[59]  Jing-Wei Mao,et al.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. , 2012, World journal of gastroenterology.

[60]  T. Sørensen,et al.  Familial occurrence of inflammatory bowel disease. , 1991, The New England journal of medicine.

[61]  P. Billings,et al.  Activation of Transforming Growth Factor β in Chondrocytes Undergoing Endochondral Ossification , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  S. Doan,et al.  EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. , 2011, The American journal of pathology.

[63]  D. Bernardo,et al.  High Levels of Proinflammatory Cytokines, but Not Markers of Tissue Injury, in Unaffected Intestinal Areas from Patients with IBD , 2009, Mediators of inflammation.

[64]  M. Khaitsa,et al.  Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease , 2007, Epidemiology and Infection.

[65]  P. Hellström,et al.  Nitric oxide pathway-related gene alterations in inflammatory bowel disease , 2012, Scandinavian journal of gastroenterology.

[66]  M. Sefton,et al.  Effect of a matrix metalloproteinase sequestering biomaterial on Caco-2 epithelial cell barrier integrity in vitro. , 2009, Acta biomaterialia.

[67]  A. Andicoechea,et al.  Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.

[68]  X. Tan,et al.  Effect of Etiasa on the expression of matrix metalloproteinase-2 and tumor necrosis factor-α in a rat model of ulcerative colitis. , 2012, Molecular medicine reports.

[69]  O. Nielsen,et al.  Inflammatory pathways of importance for management of inflammatory bowel disease. , 2014, World journal of gastroenterology.

[70]  E S Lander,et al.  Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. , 2000, American journal of human genetics.

[71]  P. Coussens,et al.  Johne's disease in cattle is associated with enhanced expression of genes encoding IL-5, GATA-3, tissue inhibitors of matrix metalloproteinases 1 and 2, and factors promoting apoptosis in peripheral blood mononuclear cells. , 2005, Veterinary immunology and immunopathology.

[72]  Jean Weissenbach,et al.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.

[73]  P. Rutgeerts,et al.  Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[74]  R. Cortivo,et al.  Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts. , 2003, Investigative ophthalmology & visual science.

[75]  G. Jena,et al.  Melatonin Reduces Ulcerative Colitis-Associated Local and Systemic Damage in Mice: Investigation on Possible Mechanisms , 2013, Digestive Diseases and Sciences.

[76]  M. Radomski,et al.  Role of Matrix Metalloproteinases in Intestinal Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[77]  S. Takai,et al.  Role of Chymase-Dependent Matrix Metalloproteinase-9 Activation in Mice with Dextran Sodium Sulfate-Induced Colitis , 2008, Journal of Pharmacology and Experimental Therapeutics.

[78]  J. González‐Gallego,et al.  Glutamine prevents fibrosis development in rats with colitis induced by 2,4,6-trinitrobenzene sulfonic acid. , 2010, The Journal of nutrition.

[79]  E. Mazzon,et al.  Melatonin reduces dinitrobenzene sulfonic acid‐induced colitis , 2001, Journal of pineal research.

[80]  C. Haglund,et al.  Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery. , 2013, World journal of gastroenterology.

[81]  A. Ouellette,et al.  Matrix Metalloproteinase-7 Activation of Mouse Paneth Cell Pro-α-defensins , 2006, Journal of Biological Chemistry.

[82]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[83]  A. Kostic,et al.  The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.

[84]  P. Rutgeerts,et al.  Neutrophil Gelatinase B–associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis , 2014, Inflammatory bowel diseases.

[85]  J. Clancy,et al.  A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation12 , 2008, The Journal of Immunology.

[86]  A. Gamian,et al.  Matrix Metalloproteinase-9: Its Interplay with Angiogenic Factors in Inflammatory Bowel Diseases , 2014, Disease markers.

[87]  J. Elguero,et al.  Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. , 2009, Bioorganic & medicinal chemistry.

[88]  S. Targan,et al.  Linkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analyses , 1999, Gut.

[89]  B. Fingleton,et al.  Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia , 2012, Laboratory Investigation.

[90]  A. Keshavarzian,et al.  The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. , 2011, The Journal of surgical research.

[91]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[92]  J. Epstein,et al.  Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease , 2009, British Journal of Nutrition.

[93]  N. Mukaida,et al.  Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice , 2012, PloS one.

[94]  C. Dietrich,et al.  Enhanced expression of MMP‐7 and MMP‐13 in inflammatory bowel disease: A precancerous potential? , 2006, Inflammatory bowel diseases.

[95]  Y. Naito,et al.  Early-stage blocking of Notch signaling inhibits the depletion of goblet cells in dextran sodium sulfate-induced colitis in mice , 2010, Journal of Gastroenterology.

[96]  Y. Chao,et al.  Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. , 2009, Toxicology and applied pharmacology.

[97]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[98]  J. Bartlett,et al.  The role of the intestinal microflora in experimental colitis. , 1977, The American journal of clinical nutrition.

[99]  C. López-Otín,et al.  Matrix Metalloprotease 8-Dependent Extracellular Matrix Cleavage at the Blood–CSF Barrier Contributes to Lethality during Systemic Inflammatory Diseases , 2012, The Journal of Neuroscience.

[100]  M. Egger,et al.  Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[101]  E. Mazzon,et al.  Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis. , 2009, Biochemical pharmacology.

[102]  J. Schölmerich,et al.  Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype. , 2007, World journal of gastroenterology.

[103]  Z. Tulassay,et al.  The Impact of Matrix Metalloproteinases and Their Tissue Inhibitors in Inflammatory Bowel Diseases , 2012, Digestive Diseases.

[104]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[105]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[106]  S. Hanauer,et al.  Double blind, placebo controlled trial of metronidazole in Crohn's disease. , 1991, Gut.

[107]  H. Verspaget,et al.  Effect of the anti‐tumor necrosis factor‐&agr; antibody infliximab on the ex vivo mucosal matrix metalloproteinase–proteolytic phenotype in inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[108]  M. Sinnamon,et al.  Essential role for mast cell tryptase in acute experimental colitis , 2010, Proceedings of the National Academy of Sciences.

[109]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[110]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[111]  N. Docherty,et al.  Fibrogenesis in Crohn's Disease , 2007, The American Journal of Gastroenterology.

[112]  B. Iwańczak,et al.  Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children. , 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[113]  J. Kang,et al.  Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. , 2011, The Journal of nutritional biochemistry.

[114]  Wei Wang,et al.  Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. , 2008, World journal of gastroenterology.

[115]  T. Karlsen,et al.  Update on primary sclerosing cholangitis. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[116]  M. Lipko,et al.  Colonic gene expression profile in NHE3-deficient mice: evidence for spontaneous distal colitis. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[117]  S. Dedhar,et al.  Integrin-linked kinase regulates cell proliferation and tumour growth in murine colitis-associated carcinogenesis , 2008, Gut.

[118]  Jack Satsangi,et al.  Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis , 2008, Gut.

[119]  D. Nguyen,et al.  Animal models of ulcerative colitis and their application in drug research , 2013, Drug design, development and therapy.

[120]  E. Roeb,et al.  Induction of matrix metalloproteinases and TLR2 and 6 in murine colon after oral exposure to Mycobacterium avium subsp. paratuberculosis. , 2012, Microbes and infection.

[121]  K. Kolho,et al.  Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease , 2010, Scandinavian journal of gastroenterology.

[122]  N. Wright,et al.  Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. , 2007, Pharmacology & therapeutics.

[123]  E. Goetzl,et al.  VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. , 2011, Cellular immunology.

[124]  E. Mazzon,et al.  Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[125]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[126]  S. Szabó,et al.  Mesalamine Restores Angiogenic Balance in Experimental Ulcerative Colitis by Reducing Expression of Endostatin and Angiostatin: Novel Molecular Mechanism for Therapeutic Action of Mesalamine , 2009, Journal of Pharmacology and Experimental Therapeutics.

[127]  C. Loddenkemper,et al.  Selective gelatinase blockage ameliorates acute DSS colitis. , 2011, European journal of microbiology & immunology.

[128]  M. Parkes,et al.  Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. , 2001, Gastroenterology.

[129]  G. Corazza,et al.  Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures , 2009, Gut.

[130]  K. Boberg,et al.  Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. , 2004, Journal of hepatology.

[131]  M. Silverberg,et al.  Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis , 2010, PloS one.

[132]  K. Asadullah,et al.  A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. , 2002, The Journal of investigative dermatology.

[133]  石田 久美 Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis , 2008 .

[134]  Hye-Jin Park,et al.  Ethanol Extract of Cordyceps militaris Grown on Germinated Soybeans Attenuates Dextran-Sodium-Sulfate- (DSS-) Induced Colitis by Suppressing the Expression of Matrix Metalloproteinases and Inflammatory Mediators , 2013, BioMed research international.

[135]  J. Roman,et al.  Matrix metalloproteinase-9 regulates MUC-2 expression through its effect on goblet cell differentiation. , 2007, Gastroenterology.

[136]  A. Mazar,et al.  Differential angiogenic regulation of experimental colitis. , 2006, The American journal of pathology.

[137]  H. Verspaget,et al.  Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)‐2 and ‐9 in Crohn's disease , 2007, Inflammatory bowel diseases.

[138]  E. Roeb,et al.  Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis , 2010, Scandinavian journal of gastroenterology.

[139]  H. Weinans,et al.  The novel vitamin D analog ZK191784 as an intestine‐ specific vitamin D antagonist , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[140]  M. Scott,et al.  TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. , 2009, Gastroenterology.

[141]  M. Milla,et al.  Role of vitamin D derivatives in intestinal tissue of patients with inflammatory bowel diseases. , 2014, Journal of Crohn's & colitis.

[142]  K. Farkas,et al.  Fecal MMP-9: A New Noninvasive Differential Diagnostic and Activity Marker in Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[143]  M. Radomski,et al.  Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. , 2014, Biochimica et biophysica acta.

[144]  R. Greenstein Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. , 2003, The Lancet. Infectious diseases.

[145]  W. Parks,et al.  Matrix metalloproteinase‐7 (matrilysin) controls neutrophil egress by generating chemokine gradients , 2008, Journal of leukocyte biology.

[146]  B. Molnár,et al.  The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis , 2011, Pathology & Oncology Research.

[147]  E. Rozengurt,et al.  Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts. , 2011, Biochemical and biophysical research communications.

[148]  C. Elson,et al.  A Novel Role for Defensins in Intestinal Homeostasis: Regulation of IL-1β Secretion1 , 2007, The Journal of Immunology.

[149]  L. Liotta,et al.  Basement membrane collagen: degradation by migrating endothelial cells. , 1983, Science.

[150]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[151]  S. Itzkowitz,et al.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[152]  J. Tajti,et al.  The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. , 2014, Journal of Crohn's & colitis.

[153]  D. Hommes,et al.  Role of matrix metalloproteinase,tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease , 2007 .

[154]  Kwang Yeon Kim,et al.  Familial occurrence of inflammatory bowel disease in Korea , 2006, Inflammatory bowel diseases.

[155]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[156]  T. Salo,et al.  Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.

[157]  C. Probert,et al.  IL-13 Promotes Collagen Accumulation in Crohn’s Disease Fibrosis by Down-Regulation of Fibroblast MMP Synthesis: A Role for Innate Lymphoid Cells? , 2012, PloS one.

[158]  A. M. Houghton,et al.  Macrophage elastase kills bacteria within murine macrophages , 2009, Nature.

[159]  R. Hershberg,et al.  Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[160]  J. Mendoza,et al.  Mycobacterium avium subspecies paratuberculosis and its relationship with Crohn's disease. , 2009, World journal of gastroenterology.

[161]  Judy H. Cho,et al.  Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease , 2007, European Journal of Human Genetics.

[162]  D. Sohn,et al.  2′,4′,6′-Tris(methoxymethoxy) chalcone protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor-α-induced intestinal epithelial inflammation via heme oxygenase 1-dependent and independent pathways , 2007 .

[163]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial , 2003 .

[164]  M. Stolte,et al.  Allelic variation of the matrix metalloproteinase‐9 gene is associated with collagenous colitis , 2011, Inflammatory bowel diseases.

[165]  L. Melton,et al.  Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.

[166]  M. Radomski,et al.  Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. , 2012, Journal of medicinal chemistry.

[167]  M. Gareau,et al.  Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis , 2012, BMC Microbiology.

[168]  G. Rogler,et al.  Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. , 2014, Journal of Crohn's & colitis.

[169]  D. Sheppard,et al.  The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1 , 2002, The Journal of cell biology.

[170]  W. Davis,et al.  Crohn's disease and Mycobacterium avium subsp. paratuberculosis: the need for a study is long overdue. , 2012, Veterinary immunology and immunopathology.

[171]  K. Kolho,et al.  Serum MMPs 7–9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease , 2012, Scandinavian journal of gastroenterology.

[172]  D. Graham,et al.  Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. , 2001, Alimentary pharmacology & therapeutics.

[173]  H. Verspaget,et al.  Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[174]  C. Hiruma-Lima,et al.  Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. , 2012, Chemico-biological interactions.

[175]  M. Sans,et al.  VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. , 2009, Gastroenterology.

[176]  M. Rojas,et al.  Selective Ablation of Matrix Metalloproteinase-2 Exacerbates Experimental Colitis: Contrasting Role of Gelatinases in the Pathogenesis of Colitis1 , 2006, The Journal of Immunology.

[177]  M. Grisham,et al.  Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[178]  K. Hahm,et al.  Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression , 2010, Cancer Prevention Research.

[179]  V. Binder,et al.  Familial occurrence and inheritance studies in inflammatory bowel disease. , 1996, The Netherlands journal of medicine.

[180]  S. Targan,et al.  A genome-wide search identifies potential new susceptibility loci for Crohn's disease. , 1999, Inflammatory bowel diseases.

[181]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[182]  P. Hunter,et al.  Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid‐based techniques: A systematic review and meta‐analysis , 2008, Inflammatory bowel diseases.

[183]  C. V. van Noorden,et al.  The role of gelatinases in colorectal cancer progression and metastasis. , 2004, Biochimica et biophysica acta.

[184]  M. Keeffe Digestive diseases and sciences , 2005, Digestive Diseases and Sciences.

[185]  V. Yang,et al.  Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice. , 2011, Gastroenterology.

[186]  A. Gasbarrini,et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.

[187]  H. Emonard,et al.  Involvement of Fibronectin Type II Repeats in the Efficient Inhibition of Gelatinases A and B by Long-chain Unsaturated Fatty Acids* , 2001, The Journal of Biological Chemistry.

[188]  P. Treuting,et al.  Serum biomarkers in a mouse model of bacterial‐induced inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[189]  F. Guarner,et al.  Transforming growth factor‐beta type 1 receptor (ALK5) and Smad proteins mediate TIMP‐1 and collagen synthesis in experimental intestinal fibrosis , 2011, The Journal of pathology.

[190]  Hiroyuki Yamamoto,et al.  The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis , 2003, Journal of Gastroenterology.

[191]  K. Jordan,et al.  A commentary on current perspectives on Mycobacterium avium subsp. paratuberculosis, Johne’s disease and Crohn’s disease: A review by Over et al. (2011) , 2012, Critical reviews in microbiology.

[192]  A. Murakami,et al.  Auraptene Decreases the Activity of Matrix Metalloproteinases in Dextran Sulfate Sodium-Induced Ulcerative Colitis in ICR Mice , 2006, Bioscience, biotechnology, and biochemistry.

[193]  L. Matrisian,et al.  Matrilysin (matrix metalloproteinase‐7) expression in ulcerative colitis–related tumorigenesis † , 2002, Molecular carcinogenesis.

[194]  P. Garg,et al.  Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[195]  B. Molnár,et al.  Peripheral Blood Based Discrimination of Ulcerative Colitis and Crohn’s Disease from Non-IBD Colitis by Genome-Wide Gene Expression Profiling , 2011, Disease markers.

[196]  O. Inatomi,et al.  Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts , 2007, Journal of Gastroenterology.

[197]  Yingde Wang,et al.  Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. , 2006, World journal of gastroenterology.

[198]  K. Imai,et al.  Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium , 2006, The Journal of pathology.

[199]  B. Sandhu,et al.  Epidemiology of inflammatory bowel diseases in childhood , 2006, Indian journal of pediatrics.

[200]  G. Batist,et al.  Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[201]  A. Di Sabatino,et al.  Matrix metalloproteinase‐3 production by gut IgG plasma cells in chronic inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[202]  S. Szabó,et al.  Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. , 2011, Life sciences.

[203]  C. Elson,et al.  Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota , 2005, Immunological reviews.

[204]  G. J. Rosa,et al.  Evidence for a Novel Gene Expression Program in Peripheral Blood Mononuclear Cells from Mycobacterium avium subsp. paratuberculosis-Infected Cattle , 2003, Infection and Immunity.

[205]  Thomas Lengauer,et al.  A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.

[206]  A. Henschen-Edman,et al.  Structural Determinants of Procryptdin Recognition and Cleavage by Matrix Metalloproteinase-7* , 2003, The Journal of Biological Chemistry.

[207]  M. Pakarinen,et al.  Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis. , 2012, World journal of gastroenterology.

[208]  G. Corazza,et al.  Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab , 2009, European journal of gastroenterology & hepatology.

[209]  D. Sauder,et al.  Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.